Extent of myometrial invasion |
|
|
|
|
|
|
|
|
|
|
|
|
<50% | 17 | (34%) | 15 | (88.2%) | 2 | (11.8%) | <0.001‡ | 15 | (88.2%) | 2 | (11.8%) | <0.001‡ |
>50% | 33 | (66%) | 7 | (21.2%) | 26 | (78.8%) | 6 | (18.2%) | 27 | (81.8%) | ||
Cervical stromal invasion |
|
|
|
|
|
|
|
|
|
|
|
|
Absent | 22 | (44%) | 17 | (77.3%) | 5 | (22.7%) | 0.005‡ | 17 | (77.3%) | 5 | (22.7%) | 0.007‡ |
Present | 28 | (56%) | 5 | (17.9%) | 23 | (82.1%) | 4 | (14.3%) | 24 | (85.7%) | ||
Parametrial extension |
|
|
|
|
|
|
|
|
|
|
|
|
Absent | 32 | (64%) | 19 | (59.4%) | 13 | (40.6%) | 0.003‡ | 19 | (59.4%) | 13 | (40.6%) | 0.009‡ |
Present | 18 | (36%) | 3 | (16.7%) | 15 | (83.3%) | 2 | (11.1%) | 16 | (88.9%) | ||
Serosal invasion |
|
|
|
|
|
|
|
|
|
|
|
|
Absent | 32 | (64%) | 19 | (59.4%) | 13 | (40.6%) | 0.049‡ | 19 | (59.4%) | 13 | (40.6%) | 0.043‡ |
Present | 18 | (36%) | 3 | (16.7%) | 15 | (83.3%) | 2 | (11.1%) | 16 | (88.9%) | ||
Adnexal invasion |
|
|
|
|
|
|
|
|
|
|
|
|
Absent | 32 | (64%) | 21 | (65.6%) | 11 | (34.4%) | 0.03‡ | 21 | (65.6%) | 11 | (34.4%) | 0.02‡ |
Present | 18 | (36%) | 1 | (5.6%) | 17 | (94.4%) | 0 | (0%) | 18 | (100%) | ||
Peritoneal cytology |
|
|
|
|
|
|
|
|
|
|
|
|
Negative | 30 | (60%) | 19 | (63.3%) | 11 | (36.7%) | 0.006‡ | 19 | (63.3%) | 11 | (36.7%) | 0.004‡ |
Positive | 20 | (40%) | 3 | (15%) | 17 | (85%) | 2 | (10%) | 18 | (90%) | ||
Lymph node |
|
|
|
|
|
|
|
|
|
|
|
|
Negative | 30 | (60%) | 19 | (63.3%) | 11 | (36.7%) | 0.009‡ | 19 | (63.3%) | 11 | (36.7%) | 0.003‡ |
Positive | 20 | (40%) | 3 | (15%) | 17 | (85%) | 2 | (10%) | 18 | (90%) | ||
Distant metastasis |
|
|
|
|
|
|
|
|
|
|
|
|
Negative | 40 | (80%) | 21 | (52.2%) | 19 | (47.5%) | 0.029‡ | 21 | (52.5%) | 19 | (47.5%) | 0.003‡ |
Positive | 10 | (20%) | 1 | (10%) | 9 | (90%) | 0 | (0%) | 10 | (100%) | ||
FIGO stage |
|
|
|
|
|
|
|
|
|
|
|
|
Stage I | 22 | (44%) | 17 | (77.3%) | 5 | (22.7%) | <0.001§ | 17 | (77.3%) | 5 | (22.7%) | <0.001§ |
Stage II | 10 | (20%) | 2 | (20%) | 8 | (80%) | 2 | (20%) | 8 | (80%) | ||
Stage III | 8 | (16%) | 2 | (25%) | 6 | (75%) | 2 | (25%) | 6 | (75%) | ||
Stage IV | 10 | (20%) | 1 | (10%) | 9 | (90%) | 1 | (10%) | 9 | (90%) | ||
CRKL |
|
|
|
|
|
|
|
|
|
|
|
|
Low | 22 | (44%) |
|
|
|
|
| 20 | (90.9%) | 2 | (9.1%) | <0.001‡ |
High | 28 | (56%) |
|
|
|
| 1 | (3.6%) | 27 | (96.4%) | ||
CK2 β |
|
|
|
|
|
|
|
|
|
|
|
|
Low | 21 | (42%) | 20 | (95.2%) | 1 | (4.8%) | <0.001‡ |
|
|
|
|
|
High | 29 | (58%) | 2 | (6.9%) | 27 | (93.1%) |
|
|
|
|